Results 251 to 260 of about 2,109 (292)
Some of the next articles are maybe not open access.
Thrombosis and Haemostasis, 2011
SummaryThe mast cell, a potent inflammatory cell type, is widely distributed over several tissues, but particularly prominent at the interface exposed to the environment to act in the first line of defense against pathogens. Upon activation mast cells release granules, which contain a large panel of mediators, including neutral proteases (e.g.
Bot, Ilze, Biessen, Erik A. L.
openaire +3 more sources
SummaryThe mast cell, a potent inflammatory cell type, is widely distributed over several tissues, but particularly prominent at the interface exposed to the environment to act in the first line of defense against pathogens. Upon activation mast cells release granules, which contain a large panel of mediators, including neutral proteases (e.g.
Bot, Ilze, Biessen, Erik A. L.
openaire +3 more sources
2007
Mast cells (MCs) are traditionally thought of as a nuisance for its host, for example, by causing many of the symptoms associated with allergic reactions. In addition, recent research has put focus on MCs for displaying harmful effects during various autoimmune disorders.
Gunnar, Pejler +3 more
openaire +2 more sources
Mast cells (MCs) are traditionally thought of as a nuisance for its host, for example, by causing many of the symptoms associated with allergic reactions. In addition, recent research has put focus on MCs for displaying harmful effects during various autoimmune disorders.
Gunnar, Pejler +3 more
openaire +2 more sources
On the Heterogeneity of Mast Cells
Pharmacology, 2008Mast cells from different locations are shown to vary in their histochemical, ultrastructural, cytochemical and functional properties. The clinical consequences of this heterogeneity and possible reasons for its origin are discussed.
openaire +2 more sources
Mast Cell–Targeting Therapies in Mast Cell Activation Syndromes
Current Allergy and Asthma ReportsProvide an overview of the expanding landscape of mast cell (MC)-targeting treatments in mast cell activation syndromes (MCAS).Tyrosine-kinase inhibitors (TKIs) targeting wild-type and mutated KIT can efficiently induce MC depletion. Avapritinib and midostaurin can also temper IgE-mediated degranulation.
Sabato, Vito +4 more
openaire +3 more sources
A brief history of masting research
Philosophical Transactions of the Royal Society B: Biological Sciences, 2021Walter D. Koenig
exaly
Mast cells and mast cell neoplasia: a review*
Histopathology, 1979K, Lennert, M R, Parwaresch
openaire +2 more sources